BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18079733)

  • 21. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
    Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
    Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
    Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U
    Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
    Mills KI; Kohlmann A; Williams PM; Wieczorek L; Liu WM; Li R; Wei W; Bowen DT; Loeffler H; Hernandez JM; Hofmann WK; Haferlach T
    Blood; 2009 Jul; 114(5):1063-72. PubMed ID: 19443663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1.
    Li B; Xu Z; Gale RP; Qin T; Zhang Y; Xiao Z
    Acta Haematol; 2013; 129(4):243-50. PubMed ID: 23328695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
    Alkharabsheh O; Patnaik MM; Gangat N; Begna KH; Alkhateeb HB; Shah MV; Hogan WJ; He R; Greipp P; Nguyen PL; Litzow MR; Al-Kali A
    Ann Hematol; 2020 Mar; 99(3):513-518. PubMed ID: 31974678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems.
    Sperr WR; Wimazal F; Kundi M; Fonatsch C; Thalhammer-Scherrer R; Schernthaner GH; Schwarzinger I; Haas OA; Geissler K; Lechner K; Valent P
    Ann Hematol; 2001 May; 80(5):272-7. PubMed ID: 11446729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classification of the myelodysplastic syndromes.
    Bennett JM
    Clin Haematol; 1986 Nov; 15(4):909-23. PubMed ID: 3471370
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
    Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
    Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
    Armand P; Kim HT; Cutler CS; Ho VT; Koreth J; Ritz J; Alyea EP; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):28-35. PubMed ID: 18158958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinico-pathological analysis of myelodysplastic syndromes according to French-American-British classification and international prognostic scoring system.
    Lau LG; Chng WJ; Liu TC; Tan LK; Ong KH; Mow BM; Kueh YK
    Ann Acad Med Singap; 2004 Sep; 33(5):589-95. PubMed ID: 15531954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
    Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
    Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
    Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
    Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
    Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.